{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T11:26:36Z","timestamp":1794396396531,"version":"4.9.0"},"reference-count":104,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,27]],"date-time":"2022-04-27T00:00:00Z","timestamp":1651017600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009227","name":"Department of Medicine, University of Toronto","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009227","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013528","name":"Diabetes Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013528","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004054","name":"King Abdulaziz University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["kireports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International Reports"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.ekir.2022.04.094","type":"journal-article","created":{"date-parts":[[2022,5,5]],"date-time":"2022-05-05T13:52:09Z","timestamp":1651758729000},"page":"1463-1476","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":225,"title":["Prescribing SGLT2 Inhibitors in Patients With CKD: Expanding Indications and Practical Considerations"],"prefix":"10.1016","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8653-6778","authenticated-orcid":false,"given":"Kevin","family":"Yau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atit","family":"Dharia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"Alrowiyti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David Z.I.","family":"Cherney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ekir.2022.04.094_bib2","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2022.04.094_bib3","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2022.04.094_bib4","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2022.04.094_bib5","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","article-title":"Cardiovascular outcomes with ertugliflozin in type 2 diabetes","volume":"383","author":"Cannon","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2022.04.094_bib6","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","article-title":"10-Year follow-up of intensive glucose control in type 2 diabetes","volume":"359","author":"Holman","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2022.04.094_bib7","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2022.04.094_bib8","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2022.04.094_bib9","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2022.04.094_bib10","doi-asserted-by":"crossref","first-page":"262","DOI":"10.7326\/0003-4819-159-4-201308200-00007","article-title":"Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis","volume":"159","author":"Vasilakou","year":"2013","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ekir.2022.04.094_bib11","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/jdi.12214","article-title":"Renal sodium glucose cotransporter 2 inhibitors as a novel therapeutic approach to treatment of type 2 diabetes: clinical data and mechanism of action","volume":"5","author":"Fujita","year":"2014","journal-title":"J\u00a0Diabetes Investig"},{"key":"10.1016\/j.ekir.2022.04.094_bib12","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1681\/ASN.2010030246","article-title":"SGLT2 mediates glucose reabsorption in the early proximal tubule","volume":"22","author":"Vallon","year":"2011","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2022.04.094_bib13","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.kint.2017.06.017","article-title":"Pooled analysis of phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin","volume":"93","author":"Cherney","year":"2018","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2022.04.094_bib14","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1111\/obr.12755","article-title":"Weight loss associated with sodium-glucose cotransporter-2 inhibition: a review of evidence and underlying mechanisms","volume":"19","author":"Lee","year":"2018","journal-title":"Obes Rev"},{"key":"10.1016\/j.ekir.2022.04.094_bib15","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1210\/jc.2011-2260","article-title":"Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin","volume":"97","author":"Bolinder","year":"2012","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.ekir.2022.04.094_bib16","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s12933-019-0852-y","article-title":"Effect of SGLT2 inhibitors on body composition, fluid status and renin-angiotensin-aldosterone system in type 2 diabetes: a prospective study using bioimpedance spectroscopy","volume":"18","author":"Schork","year":"2019","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.ekir.2022.04.094_bib17","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s40261-017-0580-6","article-title":"Clinical factors associated with initial decrease in body-fat percentage induced by add-on sodium-glucose co-transporter 2 inhibitors in patient with type 2 diabetes mellitus","volume":"38","author":"Kurinami","year":"2018","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.ekir.2022.04.094_bib18","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/dom.12670","article-title":"Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis","volume":"18","author":"Zaccardi","year":"2016","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.ekir.2022.04.094_bib19","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1007\/s00125-018-4669-0","article-title":"The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure","volume":"61","author":"Thomas","year":"2018","journal-title":"Diabetologia"},{"key":"10.1016\/j.ekir.2022.04.094_bib20","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/dom.12127","article-title":"Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes","volume":"15","author":"Lambers Heerspink","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.ekir.2022.04.094_bib21","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/1475-2840-13-28","article-title":"The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus","volume":"13","author":"Cherney","year":"2014","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.ekir.2022.04.094_bib22","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.2169\/internalmedicine.0701-17","article-title":"The SGLT2 inhibitor dapagliflozin significantly improves the peripheral microvascular endothelial function in patients with uncontrolled type 2 diabetes mellitus","volume":"57","author":"Sugiyama","year":"2018","journal-title":"Intern Med"},{"key":"10.1016\/j.ekir.2022.04.094_bib23","article-title":"Effect of sodium-glucose cotransport-2 inhibitors on blood pressure in people with type 2 diabetes mellitus: a systematic review and meta-analysis of 43 randomized control trials with 22 528 patients","volume":"6","author":"Mazidi","year":"2017","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.ekir.2022.04.094_bib24","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1111\/dom.13301","article-title":"Effects of the SGLT-2 inhibitor dapagliflozin on glomerular and tubular injury markers","volume":"20","author":"Dekkers","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.ekir.2022.04.094_bib25","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1161\/CIRCULATIONAHA.116.021887","article-title":"Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications","volume":"134","author":"Heerspink","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.ekir.2022.04.094_bib26","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1007\/s00125-014-3396-4","article-title":"Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration","volume":"57","author":"Skrtic","year":"2014","journal-title":"Diabetologia"},{"key":"10.1016\/j.ekir.2022.04.094_bib27","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s00125-016-4157-3","article-title":"Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition","volume":"60","author":"Vallon","year":"2017","journal-title":"Diabetologia"},{"key":"10.1016\/j.ekir.2022.04.094_bib28","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/S2213-8587(17)30182-1","article-title":"Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial","volume":"5","author":"Cherney","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.ekir.2022.04.094_bib29","doi-asserted-by":"crossref","first-page":"e54442","DOI":"10.1371\/journal.pone.0054442","article-title":"Effects of\u00a0SGLT2\u00a0inhibition in human kidney proximal tubular cells\u2014renoprotection in diabetic nephropathy?","volume":"8","author":"Panchapakesan","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ekir.2022.04.094_bib30","first-page":"844","article-title":"Increased hematocrit during sodium-glucose cotransporter 2 inhibitor therapy indicates recovery of tubulointerstitial function in diabetic kidneys","volume":"8","author":"Sano","year":"2016","journal-title":"J\u00a0Clin Med Res"},{"key":"10.1016\/j.ekir.2022.04.094_bib31","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.kint.2017.12.027","article-title":"Renoprotective effects of sodium-glucose cotransporter-2 inhibitors","volume":"94","author":"Heerspink","year":"2018","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2022.04.094_bib32","doi-asserted-by":"crossref","first-page":"4891","DOI":"10.1093\/eurheartj\/ehab497","article-title":"Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial","volume":"42","author":"Neuen","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ekir.2022.04.094_bib33","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1056\/NEJMoa1708337","article-title":"Effects of sotagliflozin added to insulin in patients with type 1 diabetes","volume":"377","author":"Garg","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2022.04.094_bib34","doi-asserted-by":"crossref","first-page":"e1235","DOI":"10.1210\/clinem\/dgz258","article-title":"Sotagliflozin decreases postprandial glucose and insulin concentrations by delaying intestinal glucose absorption","volume":"105","author":"Powell","year":"2020","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.ekir.2022.04.094_bib35","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2030183","article-title":"Sotagliflozin in patients with diabetes and recent worsening heart failure","volume":"384","author":"Bhatt","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2022.04.094_bib36","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1161\/CIRCULATIONAHA.121.054442","article-title":"Does SGLT1 inhibition add benefit to SGLT2 inhibition in type 2 diabetes?","volume":"144","author":"Pitt","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.ekir.2022.04.094_bib37","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJMoa2030186","article-title":"Sotagliflozin in patients with diabetes and chronic kidney disease","volume":"384","author":"Bhatt","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2022.04.094_bib38","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1111\/dom.14513","article-title":"Efficacy and safety of sotagliflozin in patients with type 2 diabetes and severe renal impairment","volume":"23","author":"Cherney","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.ekir.2022.04.094_bib39","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.kint.2020.06.024","article-title":"Executive summary of the 2020 KDIGO Diabetes Management in CKD Guideline: evidence-based advances in monitoring and treatment","volume":"98","author":"de Boer","year":"2020","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2022.04.094_bib40","doi-asserted-by":"crossref","first-page":"S125","DOI":"10.2337\/dc21-S010","article-title":"10. Cardiovascular disease and risk management","volume":"44","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ekir.2022.04.094_bib41","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.cmet.2019.04.011","article-title":"A\u00a0big win for diabetic kidney disease: CREDENCE","volume":"29","author":"Cherney","year":"2019","journal-title":"Cell Metab"},{"key":"10.1016\/j.ekir.2022.04.094_bib42","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.2215\/CJN.01130121","article-title":"Ertugliflozin and slope of chronic eGFR: prespecified analyses from the randomized VERTIS CV Trial","volume":"16","author":"Cherney","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2022.04.094_bib43","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1161\/CIRCULATIONAHA.120.051901","article-title":"Gradient of risk and associations with cardiovascular efficacy of ertugliflozin by measures of kidney function: observations from VERTIS CV","volume":"143","author":"Cherney","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.ekir.2022.04.094_bib44","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1002\/clc.23665","article-title":"Kidney outcomes using a sustained\u00a0\u226540% decline in eGFR: a meta-analysis of SGLT2 inhibitor trials","volume":"44","author":"Cherney","year":"2021","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.ekir.2022.04.094_bib45","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.34067\/KID.0001172021","article-title":"eGFR decline after SGLT2 inhibitor initiation: the tortoise and the hare reimagined","volume":"2","author":"Meraz-Mu\u00f1oz","year":"2021","journal-title":"Kidney360"},{"key":"10.1016\/j.ekir.2022.04.094_bib46","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2022.04.094_bib47","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2022.04.094_bib48","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1038\/s41581-022-00535-6","article-title":"Kidney and heart failure outcomes associated with SGLT2 inhibitor use","volume":"18","author":"van der Aart-van der Beek","year":"2022","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.ekir.2022.04.094_bib49","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/s41591-021-01659-1","article-title":"The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial","volume":"28","author":"Voors","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.ekir.2022.04.094_bib50","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S2213-8587(19)30384-5","article-title":"Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study","volume":"8","author":"Heerspink","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.ekir.2022.04.094_bib51","doi-asserted-by":"crossref","first-page":"m1186","DOI":"10.1136\/bmj.m1186","article-title":"Use of sodium-glucose co-transporter 2 inhibitors and risk of serious renal events: Scandinavian cohort study","volume":"369","author":"Pasternak","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.ekir.2022.04.094_bib52","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/dom.14239","article-title":"Renal outcomes and all-cause death associated with sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL 3 Korea)","volume":"23","author":"Koh","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.ekir.2022.04.094_bib53","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.kint.2021.09.005","article-title":"A\u00a0pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function","volume":"101","author":"Heerspink","year":"2022","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2022.04.094_bib54","doi-asserted-by":"crossref","first-page":"E351","DOI":"10.1503\/cmaj.191283","article-title":"Use of sodium-glucose cotransporter-2 inhibitors and risk of acute kidney injury in older adults with diabetes: a population-based cohort study","volume":"192","author":"Iskander","year":"2020","journal-title":"CMAJ"},{"key":"10.1016\/j.ekir.2022.04.094_bib55","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.kint.2018.05.026","article-title":"Sodium glucose cotransporter 2 inhibition and renal ischemia: implications for future clinical trials","volume":"94","author":"van Raalte","year":"2018","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2022.04.094_bib56","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S2213-8587(19)30256-6","article-title":"SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"7","author":"Neuen","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.ekir.2022.04.094_bib57","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1093\/ckj\/sfy090","article-title":"The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study","volume":"11","author":"Herrington","year":"2018","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.ekir.2022.04.094_bib58","first-page":"1","article-title":"Design, recruitment, and baseline characteristics of the EMPA-KIDNEY trial","author":"Herrington","year":"2022","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2022.04.094_bib60","doi-asserted-by":"crossref","first-page":"F412","DOI":"10.1152\/ajprenal.00445.2017","article-title":"Dapagliflozin in focal segmental glomerulosclerosis: a combined human-rodent pilot study","volume":"314","author":"Rajasekeran","year":"2018","journal-title":"Am J Physiol Ren Physiol"},{"key":"10.1016\/j.ekir.2022.04.094_bib61","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/S2213-8587(20)30162-5","article-title":"Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial","volume":"8","author":"Cherney","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.ekir.2022.04.094_bib62","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1093\/ndt\/gfaa234","article-title":"The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics","volume":"35","author":"Wheeler","year":"2020","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2022.04.094_bib63","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.kint.2021.03.033","article-title":"A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy","volume":"100","author":"Wheeler","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2022.04.094_bib64","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.kint.2021.04.002","article-title":"SGLT-2 inhibition in IgA nephropathy: the new standard of care?","volume":"100","author":"Barratt","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2022.04.094_bib65","first-page":"1","article-title":"Safety and efficacy of dapagliflozin in patients with focal segmental glomerulosclerosis: a prespecified analysis of the DAPA-CKD trial","author":"Wheeler","year":"2022","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2022.04.094_bib66","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/S2213-8587(21)00243-6","article-title":"Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial","volume":"9","author":"Jongs","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.ekir.2022.04.094_bib67","first-page":"1","article-title":"SGLT2 inhibition requires reconsideration of fundamental paradigms in chronic kidney disease, diabetic nephropathy, IgA nephropathy and podocytopathies with FSGS lesions","author":"Anders","year":"2020","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2022.04.094_bib68","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1111\/dom.13648","article-title":"Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and meta-analysis","volume":"21","author":"Toyama","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.ekir.2022.04.094_bib69","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13098-020-0516-9","article-title":"Impact of sodium-glucose cotransporter 2 inhibitors on renal function in participants with type 2 diabetes and chronic kidney disease with normoalbuminuria","volume":"12","author":"Nakamura","year":"2020","journal-title":"Diabetol Metab Syndr"},{"key":"10.1016\/j.ekir.2022.04.094_bib70","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1111\/dom.13820","article-title":"Sodium glucose cotransporter 2 inhibitors and risk of genital mycotic and urinary tract infection: a population-based study of older women and men with diabetes","volume":"21","author":"Lega","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.ekir.2022.04.094_bib71","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s00592-018-1116-0","article-title":"SGLT-2 inhibitors and the risk of infections: a systematic review and meta-analysis of randomized controlled trials","volume":"55","author":"Puckrin","year":"2018","journal-title":"Acta Diabetol"},{"key":"10.1016\/j.ekir.2022.04.094_bib72","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.pcd.2017.06.004","article-title":"Clinical risk factors predicting genital fungal infections with sodium-glucose cotransporter 2 inhibitor treatment: the ABCD nationwide dapagliflozin audit","volume":"12","author":"Thong","year":"2018","journal-title":"Prim Care Diabetes"},{"key":"10.1016\/j.ekir.2022.04.094_bib73","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1177\/1060028020951928","article-title":"Prevention and management of genital mycotic infections in the setting of sodium-glucose cotransporter 2 inhibitors","volume":"55","author":"Engelhardt","year":"2021","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.ekir.2022.04.094_bib74","doi-asserted-by":"crossref","first-page":"764","DOI":"10.7326\/M19-0085","article-title":"Fournier gangrene associated with sodium-glucose cotransporter-2 inhibitors: a review of spontaneous postmarketing cases","volume":"170","author":"Bersoff-Matcha","year":"2019","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ekir.2022.04.094_bib75","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1111\/dom.13900","article-title":"Fournier\u2019s gangrene and sodium-glucose co-transporter-2 inhibitors: a meta-analysis of randomized controlled trials","volume":"22","author":"Silverii","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.ekir.2022.04.094_bib76","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.diabres.2013.12.052","article-title":"Genital and urinary tract infections in diabetes: impact of pharmacologically induced glucosuria","volume":"103","author":"Geerlings","year":"2014","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.ekir.2022.04.094_bib77","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/j.jdiacomp.2015.07.011","article-title":"Efficacy and safety of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes: a meta-analysis of randomized controlled trials for 1 to 2years","volume":"29","author":"Liu","year":"2015","journal-title":"J\u00a0Diabetes Complications"},{"key":"10.1016\/j.ekir.2022.04.094_bib78","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1111\/dom.13424","volume":"20","author":"Ryan","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.ekir.2022.04.094_bib79","doi-asserted-by":"crossref","first-page":"e4","DOI":"10.2337\/dc17-1551","article-title":"Empagliflozin and assessment of lower-limb amputations in the EMPA-REG OUTCOME trial","volume":"41","author":"Inzucchi","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ekir.2022.04.094_bib80","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1111\/dom.13124","article-title":"Dapagliflozin in patients with type 2 diabetes mellitus: a pooled analysis of safety data from phase IIb\/III clinical trials","volume":"20","author":"Jabbour","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.ekir.2022.04.094_bib81","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1210\/jc.2015-3167","article-title":"Effects of canagliflozin on fracture risk in patients with type 2 diabetes mellitus","volume":"101","author":"Watts","year":"2016","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.ekir.2022.04.094_bib82","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1007\/s00198-005-1909-1","article-title":"Bone mineral density and fracture risk in type-2 diabetes mellitus: the Rotterdam Study","volume":"16","author":"de Liefde","year":"2005","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.ekir.2022.04.094_bib83","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1359\/jbmr.081207","article-title":"Diabetic patients have an increased risk of vertebral fractures independent of BMD or diabetic complications","volume":"24","author":"Yamamoto","year":"2009","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.ekir.2022.04.094_bib84","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s13300-019-00724-w","article-title":"Sodium-glucose co-transporter 2 inhibitors and fracture risk","volume":"11","author":"Erythropoulou-Kaltsidou","year":"2020","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.ekir.2022.04.094_bib85","doi-asserted-by":"crossref","first-page":"532","DOI":"10.2337\/dc15-1995","article-title":"Diabetic ketoacidosis with canagliflozin, a sodium-glucose cotransporter 2 inhibitor, in patients with type 1 diabetes","volume":"39","author":"Peters","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ekir.2022.04.094_bib86","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.2337\/dc18-1087","article-title":"Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: the DEPICT-1 52-week study","volume":"41","author":"Dandona","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ekir.2022.04.094_bib87","doi-asserted-by":"crossref","first-page":"e2924","DOI":"10.1002\/dmrr.2924","article-title":"Ketoacidosis associated with SGLT2 inhibitor treatment: analysis of FAERS data","volume":"33","author":"Blau","year":"2017","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1016\/j.ekir.2022.04.094_bib88","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.2215\/CJN.17621120","article-title":"Euglycemic ketoacidosis as a complication of SGLT2 inhibitor therapy","volume":"16","author":"Palmer","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2022.04.094_bib89","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.2215\/CJN.02480221","article-title":"Clinical implications of an acute dip in eGFR after SGLT2 inhibitor initiation","volume":"16","author":"Heerspink","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2022.04.094_bib90","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1053\/j.ajkd.2020.05.014","article-title":"We can finally stop worrying about SGLT2 inhibitors and acute kidney injury","volume":"76","author":"Sridhar","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2022.04.094_bib91","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1161\/CIRCULATIONAHA.120.045691","article-title":"Empagliflozin in heart failure: diuretic and cardiorenal effects","volume":"142","author":"Griffin","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.ekir.2022.04.094_bib92","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.cmet.2020.06.014","article-title":"SGLT2 inhibitor: not a traditional diuretic for heart failure","volume":"32","author":"Verma","year":"2020","journal-title":"Cell Metab"},{"key":"10.1016\/j.ekir.2022.04.094_bib93","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1161\/CIRCULATIONAHA.120.048739","article-title":"Renal and cardiovascular effects of SGLT2 inhibition in combination with loop diuretics in patients with Type 2 diabetes and chronic heart failure: the RECEDE-CHF trial","volume":"142","author":"Mordi","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.ekir.2022.04.094_bib94","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.cmet.2016.06.009","article-title":"The cardiovascular biology of glucagon-like peptide-1","volume":"24","author":"Drucker","year":"2016","journal-title":"Cell Metab"},{"key":"10.1016\/j.ekir.2022.04.094_bib95","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1007\/s00125-010-2028-x","article-title":"Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes","volume":"54","author":"Kodera","year":"2011","journal-title":"Diabetologia"},{"issue":"suppl 1","key":"10.1016\/j.ekir.2022.04.094_bib96","doi-asserted-by":"crossref","first-page":"2S20","DOI":"10.1016\/S1262-3636(17)30069-1","article-title":"The potential and pitfalls of GLP-1 receptor agonists for renal protection in type 2 diabetes","volume":"43","author":"Thomas","year":"2017","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.ekir.2022.04.094_bib97","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1161\/CIRCULATIONAHA.118.038868","article-title":"Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus","volume":"139","author":"Zelniker","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.ekir.2022.04.094_bib98","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/S2213-8587(18)30023-8","article-title":"Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial","volume":"6","author":"Ludvik","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.ekir.2022.04.094_bib99","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/S2213-8587(19)30066-X","article-title":"Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial","volume":"7","author":"Zinman","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.ekir.2022.04.094_bib100","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s12933-019-0942-x","article-title":"Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: insights from the EXSCEL trial","volume":"18","author":"Clegg","year":"2019","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.ekir.2022.04.094_bib101","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.ekir.2021.12.013","article-title":"The kidney protective effects of the sodium-glucose cotransporter-2 inhibitor, dapagliflozin, are present in patients with CKD treated with mineralocorticoid receptor antagonists","volume":"7","author":"Provenzano","year":"2022","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ekir.2022.04.094_bib102","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1016\/S0140-6736(19)30772-X","article-title":"Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial","volume":"393","author":"Heerspink","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ekir.2022.04.094_bib103","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.transproceed.2019.11.007","article-title":"Outcomes of SGLT2 inhibitors use in diabetic renal transplant patients","volume":"52","author":"AlKindi","year":"2020","journal-title":"Transplant Proc"},{"key":"10.1016\/j.ekir.2022.04.094_bib104","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1159\/000501854","article-title":"Sodium-glucose cotransporter 2 (SGLT2) inhibition in kidney transplant recipients with diabetes mellitus","volume":"44","author":"Mahling","year":"2019","journal-title":"Kidney Blood Press Res"},{"key":"10.1016\/j.ekir.2022.04.094_bib105","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/s41581-019-0173-0","article-title":"Considerations for SGLT2 inhibitor use in post-transplantation diabetes","volume":"15","author":"Hecking","year":"2019","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.ekir.2022.04.094_bib106","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of Finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N\u00a0Engl J Med"}],"container-title":["Kidney International Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024922013729?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024922013729?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T03:40:41Z","timestamp":1762832441000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468024922013729"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":104,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["S2468024922013729"],"URL":"https:\/\/doi.org\/10.1016\/j.ekir.2022.04.094","relation":{},"ISSN":["2468-0249"],"issn-type":[{"value":"2468-0249","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prescribing SGLT2 Inhibitors in Patients With CKD: Expanding Indications and Practical Considerations","name":"articletitle","label":"Article Title"},{"value":"Kidney International Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ekir.2022.04.094","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 International Society of Nephrology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}